Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Chronic Intestinal Pseudo-obstruction
jRCT2031190137Phase 2Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic intestinal pseudo-obstruction (CIPO) comparing Rifaximin arm with Placebo arm (2 arms). Primary endpoints: Improvement ratio in abdominal bloating score in Global Symptomatic Score (GSS) at 4 weeks and Improvement ratio in gastrointestinal symptoms score at 4 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
rifaximin
03
Conditions
chronic intestinal pseudo-obstruction (CIPO)
Beyond the preview
Go deeper on jRCT2031190137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190137.